Voyager Therapeutics (VYGR) EBIAT: 2015-2025
Historic EBIAT for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to -$27.9 million.
- Voyager Therapeutics' EBIAT fell 208.40% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 589.88%. This contributed to the annual value of -$65.0 million for FY2024, which is 149.12% down from last year.
- According to the latest figures from Q3 2025, Voyager Therapeutics' EBIAT is -$27.9 million, which was up 16.45% from -$33.4 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' EBIAT registered a high of $124.0 million during Q1 2023, and its lowest value of -$34.5 million during Q4 2024.
- Moreover, its 3-year median value for EBIAT was -$22.2 million (2023), whereas its average is -$2.3 million.
- Its EBIAT has fluctuated over the past 5 years, first crashed by 513.84% in 2022, then surged by 681.85% in 2023.
- Voyager Therapeutics' EBIAT (Quarterly) stood at $5.7 million in 2021, then tumbled by 513.84% to -$23.6 million in 2022, then spiked by 338.70% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then crashed by 208.40% to -$27.9 million in 2025.
- Its last three reported values are -$27.9 million in Q3 2025, -$33.4 million for Q2 2025, and -$31.0 million during Q1 2025.